Taken together, the data suggest targeting FBXO21 could inhibit canonical PI3K signaling and impedes growth of AML, but may also impede growth of other cancer sub-types dependent on canonical PI3K signaling. This evidence concerns the gene FBXO21 and acute myeloid leukemia.